ログイン

HISTOPATHOLOGY & MT LAWS PROGRESS EXAM PART 2

HISTOPATHOLOGY & MT LAWS PROGRESS EXAM PART 2
52問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    Beneficence is: * 0/1 Providing informed consent Conducting walk-throughs Addressing workplace bullying and violence Not singling our workers/groups for hazardous duties

    Conducting walk-throughs

  • 2

    Nonmaleficence is: * 1/1 Providing informed consent Conducting walk-throughs Addressing workplace bullying and violence Not singling our workers/groups for hazardous duties

    Addressing workplace bullying and violence

  • 3

    During acute inflammation, histamine-induced increased vascular permeability causes the formation of exudates (inflammatory edema). Which one of the listed cell types is the most likely source of the histamine that causes the increased vascular permeability? * 0/1 Endothelial cells Fibroblasts Lymphocytes Mast cells Neutrophils

    Mast cells

  • 4

    What type of leukocyte actively participates in acute inflammatory processes and contains myeloperoxidase within its primary (azurophilic) granules and alkaline phosphatase in its secondary (specific) granules? * 0/1 Neutrophils Eosinophils Monocytes Lymphocytes Plasma cells

    Neutrophils

  • 5

    Formalin fixes tissue by: * 0/1 Causing a loss of color Forming cross links Forming formic acid Facilitating numerous staining techniques

    Forming cross links

  • 6

    The primary purpose of fixation is: * 0/1 Preservation of carbohydrates Coagulation of lipids Removal of tissue fluids Stabilization of proteins

    Stabilization of proteins

  • 7

    Microscopic view of a formalin-fixed tissue section demonstrates fine brown to black artifactual pigment. This would have been prevented if the formalin solution had been made: * 0/1 Alkaline Just prior to use Acidic Neutral

    Neutral

  • 8

    To prevent the formation of formalin pigment in tissues, formalin should be: * 1/1 Heated Cooled Buffered Acidified

    Buffered

  • 9

    A physical agent used in fixation is: * 1/1 Stabilization of proteins Heat Coagulation Alcohol

    Heat

  • 10

    For good fixation it is recommended that the tissue be no larger than: * 0/1 2 cm square and 1-2 mm thick 2 cm square and 3-4 mm thick 3 cm square and 1-2 mm thick 3 cm square and 3-4 mm thick

    2 cm square and 3-4 mm thick

  • 11

    To make a 10% formalin solution, how many mL of water should be added to 300 mL of 37%-40% formaldehyde solution? * 0/1 1800 2500 2700 3600

    2700

  • 12

    Which of the following is NOT a constituent of 10% neutral buffered formalin? * 0/1 Sodium phosphate trihydrate Sodium phosphate dibasic Sodium phosphate monobasic 37%-40% formaldehyde

    Sodium phosphate trihydrate

  • 13

    10% formalin contains approximately what percentage of formaldehyde? * 1/1 4 10 37 100

    4

  • 14

    Routine paraffin sections are cut at what micrometer (micron) setting? * 1/1 1 to 3 4 to 6 7 to 9 10 to 15

    4 to 6

  • 15

    When liver is cut in the cryostat, the sections obtained are alternately thick and thin, with a distinct "venetian blind" effect. The most probable cause is that the: * 1/1 Anti-roll plate is adjusted wrong Block is too cold Knife is dull Liver is fatty

    Knife is dull

  • 16

    Which of the following histological features is unique to cardiac muscle? * 1/1 Cross-striations Peripherally located nuclei Intercalated discs Non-branching fibers

    Intercalated discs

  • 17

    The connective tissue cells actively involved in wound healing are: * 1/1 Plasma cells Mast cells Macrophages Fibroblasts

    Fibroblasts

  • 18

    The acid used in the Prussian blue reaction is: * 0/1 Acetic acid Hydrochloric acid Nitric acid Sulfuric acid

    Hydrochloric acid

  • 19

    The pigment commonly known as "wear and tear pigment" or "brown atrophy" is: * 1/1 Hemofuscin Ceroid Lipofuscin Hemosiderin

    Lipofuscin

  • 20

    Antibody molecules can belong to one of five immunoglobulin classes. The antibody class most frequently used in immunofluorescent and immunoenzyme staining is: * 1/1 IgM IgE IgG IgA

    IgG

  • 21

    In immunoperoxidase staining of formalin-fixed tissue, enzyme pretreatment of antigens: * 1/1 Enhances background staining Reactivates antigens and enhances primary staining Is needed to demonstrate all antigens Has precise end-points

    Reactivates antigens and enhances primary staining

  • 22

    In immunoperoxidase procedures, excess background staining can occur as a result of nonspecific binding of protein to the specimen. This background staining can be reduced by: * 1/1 Using more concentrated primary antibody Using whole serum antibodies Incubating for a shorter time in the primary antibody Applying nonimmune serum from the same animal species as the secondary antibody prior to staining

    Applying nonimmune serum from the same animal species as the secondary antibody prior to staining

  • 23

    The volume of fixative should exceed the volume of the tissue by: * 1/1 1 to 2 times 5 to 10 times 10 to 20 times 25 to 50 times

    10 to 20 times

  • 24

    To prepare a 10% solution of formalin, which of the following amounts of water should be added to 100 mL of stock formaldehyde: * 1/1 1000 mL 900 mL 450 mL 10 mL

    900 mL

  • 25

    Carnoy fluid is prepared with acetic acid, alcohol, and: * 1/1 Chloroform Fromalin Acetone Osmium tetroxide

    Chloroform

  • 26

    Most commonly, the paraffin used for embedding tissues is kept at approximately: * 0/1 37C 52C 60C 65C

    60C

  • 27

    A good paraffin for routine use is one with a melting point of: * 0/1 50 to 52C 55 to 58C 60 to 62C 63 to 65C

    55 to 58C

  • 28

    The most common temperature for floating sections on a flotation bath is approximately: * 1/1 15 to 20C 35 to 40C 45 to 50C 55 to 60C

    45 to 50C

  • 29

    During the morning rush, your laboratory manager comes into the laboratory and starts explaining a new policy regarding vacation requests. Word spreads of the change throughout the day, and the message has changed somewhat. Several in the laboratory are upset and complain to the laboratory man- ager. Which of the following actions is the most appropriate way to handle such a situation? * 1/1 Nothing should be changed, it was handled appropriately The manager should have posted the change ont he bulletin board in the break room The manager should have announced the policy on each shift The manager should have discussed and distributed the policy at a laboratory meeting, or several laboratory meetings, so that all employees heard the policy from the manager

    The manager should have discussed and distributed the policy at a laboratory meeting, or several laboratory meetings, so that all employees heard the policy from the manager

  • 30

    What is the most important role of the manager in charge? 0/1 Independent decision making Communication Informal discussions None of the above

    Communication

  • 31

    You are the lead chemistry MLS. Your laboratory manager has asked you to evaluate two new methods for cholesterol analysis. In your evaluation, you found that method A was very accurate and precise and that method B was not very accurate and precise. However, the laboratory will make more money by investing in method B. Which of the following decisions would exhibit professionalism? * 1/1 Recommend method A to your laboratory manager. It is important that the laboratory produce the most accurate and precise results Recommend method B to your laboratory manager. It is important that the laboratory make as much money as possible State that you are unable to make a recommendation, because no difference in the methods was noted Recommend that you need more time to evaluate both methods

    Recommend method A to your laboratory manager. It is important that the laboratory produce the most accurate and precise results

  • 32

    The most important diagnosis and therapeutic management decision tool used to interpret test results is: * 1/1 Statistical analysis Reference intervals Specimen acceptability The age of a patient

    Reference intervals

  • 33

    Which of these attributes is the advantage for adding point-of-care testing? * 1/1 Higher test accuracy Lower costs Faster TAT More skilled test personnel

    Faster TAT

  • 34

    A benefit of microassays, such as point-of-care methods, include: * 0/1 Increased analytical reliability Reduced sample volume Increased diagnostic specificity Reduced numbers of repeated tests

    Reduced sample volume

  • 35

    Flammable and combustible liquids in containers 5 gallons and more should be stored in: * 0/1 A flammable safety cabinet vented to room air A nonexplosion proof refrigerator A fume hood An approved safety can

    An approved safety can

  • 36

    Which of the following is the best choice for decontaminating bench tops contaminated by the AIDS virus? * 1/1 Sodium hypochlorite bleach Formalin Quaternary ammonium compound 100% alcohol

    Sodium hypochlorite bleach

  • 37

    When processing specimens for mycobacterial testing, what specific engineering control must be used? * 1/1 Horizontal laminar flow hood Barrier protection only Biological safety cabinet Fume hood

    Biological safety cabinet

  • 38

    An index of precision is statistically known as the: * 0/1 Median Mean Standard deviation Coefficient of variation

    Coefficient of variation

  • 39

    Friction against a rough surface: * 1/1 Laceration Hematoma Contusion Abrasion

    Abrasion

  • 40

    All of the following are composition of Bouin’s fluid except: * 1/1 Ethanol Glacial acetic acid Saturated aqueous solution of picric acid Formaldehyde

    Ethanol

  • 41

    Miscible with paraffin: * 0/1 Distilled water Ethanol Formalin Xylene

    Xylene

  • 42

    The precision of an instrument is validated by: * 0/1 Running the same sample multiple times Performing serial dilutions Processing unknown specimens Monitoring normal and abnormal control

    Running the same sample multiple times

  • 43

    To prevent injury, a safe lab work practice is to: * 1/1 Secure long hair and jewelry Store well-wrapped food in the supply refrigerator Wear contact lenses for eye protection Wear comfortable, rubber-bottomed, open-weaved shoes

    Secure long hair and jewelry

  • 44

    Safe handling and disposal of laboratory generated infectious waste require: * 0/1 Disinfection of all waste Thorough mixing of infectious and noninfectious waste Separation of infectious and noninfectious waste Incineration of all waste

    Separation of infectious and noninfectious waste

  • 45

    Paper or electronic report of lab results must include: * 0/1 The name of the person who collected the specimen The test price A pathologist's signature The name and address of the testing laboratory

    The name and address of the testing laboratory

  • 46

    The laboratory manager receives a complaint from the ICU about turnaround times for coagulation tests. The first step in problem solving should be: * 1/1 Gather data on current times by shift Talk to staff about various solutions Perform root cause analysis Draw a process map to send to the ICU explaining why it takes so long

    Gather data on current times by shift

  • 47

    A technologist repeatedly misses tubercle bacilli when examining stained smears for acid-fast bacilli. What plan of action should the supervisor first take to correct this problem? * 1/1 Issue a written warning Send the employee to a workshop to improve his/her knowledge Review the diagnostic criteria with the employee and monitor progress Reassign employee to another part of the laboratory

    Review the diagnostic criteria with the employee and monitor progress

  • 48

    In quality control, ±2 standard deviations from the mean includes what percentage of the sample population? * 1/1 50% 75% 95% 98%

    95%

  • 49

    The following data are calculated on a series of 30 determinations of a serum uric acid control: mean = 5.8 mg/dl, 1 standard deviation = 0.15 mg/dl. If confidence limits are set at ±2 standard deviations, which of these ranges represents the allowable limits for the control? * 0/1 5.65 to 5.95 mg/dl 5.35 to 6.25 mg/dl 5.50 to 6.10 mg/dl 5.70 to 5.90 mg/dl

    5.50 to 6.10 mg/dl

  • 50

    Upon completion of a run of cholesterol tests, the technician recognizes that the controls are not within the 2 standard deviations confidence range. What is the appropriate course of action? * 0/1 Report the results without any other action Run a new set of controls Run a new set of controls and repeat specimens Recalibrate instrument and run controls

    Run a new set of controls and repeat specimens

  • 51

    Diagnostic specificity is defined as the percentage of individuals: * 0/1 With a given disease who have a positive result by a given test Without a given disease who have a negative result by a given test With a given disease who have a negative result by a given test Without a given disease who have a positive result by a given test

    Without a given disease who have a negative result by a given test

  • 52

    Which of the following statements about analytical (examination) errors is true? * 0/1 Analytical laboratory errors are easy for ordering providers to detect Analytical errors almost never happen in a CLIA accredited laboratory Analytical errors are not obvious to providers Analytical errors can be caused by poor patient preparation

    Analytical errors are not obvious to providers

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    Beneficence is: * 0/1 Providing informed consent Conducting walk-throughs Addressing workplace bullying and violence Not singling our workers/groups for hazardous duties

    Conducting walk-throughs

  • 2

    Nonmaleficence is: * 1/1 Providing informed consent Conducting walk-throughs Addressing workplace bullying and violence Not singling our workers/groups for hazardous duties

    Addressing workplace bullying and violence

  • 3

    During acute inflammation, histamine-induced increased vascular permeability causes the formation of exudates (inflammatory edema). Which one of the listed cell types is the most likely source of the histamine that causes the increased vascular permeability? * 0/1 Endothelial cells Fibroblasts Lymphocytes Mast cells Neutrophils

    Mast cells

  • 4

    What type of leukocyte actively participates in acute inflammatory processes and contains myeloperoxidase within its primary (azurophilic) granules and alkaline phosphatase in its secondary (specific) granules? * 0/1 Neutrophils Eosinophils Monocytes Lymphocytes Plasma cells

    Neutrophils

  • 5

    Formalin fixes tissue by: * 0/1 Causing a loss of color Forming cross links Forming formic acid Facilitating numerous staining techniques

    Forming cross links

  • 6

    The primary purpose of fixation is: * 0/1 Preservation of carbohydrates Coagulation of lipids Removal of tissue fluids Stabilization of proteins

    Stabilization of proteins

  • 7

    Microscopic view of a formalin-fixed tissue section demonstrates fine brown to black artifactual pigment. This would have been prevented if the formalin solution had been made: * 0/1 Alkaline Just prior to use Acidic Neutral

    Neutral

  • 8

    To prevent the formation of formalin pigment in tissues, formalin should be: * 1/1 Heated Cooled Buffered Acidified

    Buffered

  • 9

    A physical agent used in fixation is: * 1/1 Stabilization of proteins Heat Coagulation Alcohol

    Heat

  • 10

    For good fixation it is recommended that the tissue be no larger than: * 0/1 2 cm square and 1-2 mm thick 2 cm square and 3-4 mm thick 3 cm square and 1-2 mm thick 3 cm square and 3-4 mm thick

    2 cm square and 3-4 mm thick

  • 11

    To make a 10% formalin solution, how many mL of water should be added to 300 mL of 37%-40% formaldehyde solution? * 0/1 1800 2500 2700 3600

    2700

  • 12

    Which of the following is NOT a constituent of 10% neutral buffered formalin? * 0/1 Sodium phosphate trihydrate Sodium phosphate dibasic Sodium phosphate monobasic 37%-40% formaldehyde

    Sodium phosphate trihydrate

  • 13

    10% formalin contains approximately what percentage of formaldehyde? * 1/1 4 10 37 100

    4

  • 14

    Routine paraffin sections are cut at what micrometer (micron) setting? * 1/1 1 to 3 4 to 6 7 to 9 10 to 15

    4 to 6

  • 15

    When liver is cut in the cryostat, the sections obtained are alternately thick and thin, with a distinct "venetian blind" effect. The most probable cause is that the: * 1/1 Anti-roll plate is adjusted wrong Block is too cold Knife is dull Liver is fatty

    Knife is dull

  • 16

    Which of the following histological features is unique to cardiac muscle? * 1/1 Cross-striations Peripherally located nuclei Intercalated discs Non-branching fibers

    Intercalated discs

  • 17

    The connective tissue cells actively involved in wound healing are: * 1/1 Plasma cells Mast cells Macrophages Fibroblasts

    Fibroblasts

  • 18

    The acid used in the Prussian blue reaction is: * 0/1 Acetic acid Hydrochloric acid Nitric acid Sulfuric acid

    Hydrochloric acid

  • 19

    The pigment commonly known as "wear and tear pigment" or "brown atrophy" is: * 1/1 Hemofuscin Ceroid Lipofuscin Hemosiderin

    Lipofuscin

  • 20

    Antibody molecules can belong to one of five immunoglobulin classes. The antibody class most frequently used in immunofluorescent and immunoenzyme staining is: * 1/1 IgM IgE IgG IgA

    IgG

  • 21

    In immunoperoxidase staining of formalin-fixed tissue, enzyme pretreatment of antigens: * 1/1 Enhances background staining Reactivates antigens and enhances primary staining Is needed to demonstrate all antigens Has precise end-points

    Reactivates antigens and enhances primary staining

  • 22

    In immunoperoxidase procedures, excess background staining can occur as a result of nonspecific binding of protein to the specimen. This background staining can be reduced by: * 1/1 Using more concentrated primary antibody Using whole serum antibodies Incubating for a shorter time in the primary antibody Applying nonimmune serum from the same animal species as the secondary antibody prior to staining

    Applying nonimmune serum from the same animal species as the secondary antibody prior to staining

  • 23

    The volume of fixative should exceed the volume of the tissue by: * 1/1 1 to 2 times 5 to 10 times 10 to 20 times 25 to 50 times

    10 to 20 times

  • 24

    To prepare a 10% solution of formalin, which of the following amounts of water should be added to 100 mL of stock formaldehyde: * 1/1 1000 mL 900 mL 450 mL 10 mL

    900 mL

  • 25

    Carnoy fluid is prepared with acetic acid, alcohol, and: * 1/1 Chloroform Fromalin Acetone Osmium tetroxide

    Chloroform

  • 26

    Most commonly, the paraffin used for embedding tissues is kept at approximately: * 0/1 37C 52C 60C 65C

    60C

  • 27

    A good paraffin for routine use is one with a melting point of: * 0/1 50 to 52C 55 to 58C 60 to 62C 63 to 65C

    55 to 58C

  • 28

    The most common temperature for floating sections on a flotation bath is approximately: * 1/1 15 to 20C 35 to 40C 45 to 50C 55 to 60C

    45 to 50C

  • 29

    During the morning rush, your laboratory manager comes into the laboratory and starts explaining a new policy regarding vacation requests. Word spreads of the change throughout the day, and the message has changed somewhat. Several in the laboratory are upset and complain to the laboratory man- ager. Which of the following actions is the most appropriate way to handle such a situation? * 1/1 Nothing should be changed, it was handled appropriately The manager should have posted the change ont he bulletin board in the break room The manager should have announced the policy on each shift The manager should have discussed and distributed the policy at a laboratory meeting, or several laboratory meetings, so that all employees heard the policy from the manager

    The manager should have discussed and distributed the policy at a laboratory meeting, or several laboratory meetings, so that all employees heard the policy from the manager

  • 30

    What is the most important role of the manager in charge? 0/1 Independent decision making Communication Informal discussions None of the above

    Communication

  • 31

    You are the lead chemistry MLS. Your laboratory manager has asked you to evaluate two new methods for cholesterol analysis. In your evaluation, you found that method A was very accurate and precise and that method B was not very accurate and precise. However, the laboratory will make more money by investing in method B. Which of the following decisions would exhibit professionalism? * 1/1 Recommend method A to your laboratory manager. It is important that the laboratory produce the most accurate and precise results Recommend method B to your laboratory manager. It is important that the laboratory make as much money as possible State that you are unable to make a recommendation, because no difference in the methods was noted Recommend that you need more time to evaluate both methods

    Recommend method A to your laboratory manager. It is important that the laboratory produce the most accurate and precise results

  • 32

    The most important diagnosis and therapeutic management decision tool used to interpret test results is: * 1/1 Statistical analysis Reference intervals Specimen acceptability The age of a patient

    Reference intervals

  • 33

    Which of these attributes is the advantage for adding point-of-care testing? * 1/1 Higher test accuracy Lower costs Faster TAT More skilled test personnel

    Faster TAT

  • 34

    A benefit of microassays, such as point-of-care methods, include: * 0/1 Increased analytical reliability Reduced sample volume Increased diagnostic specificity Reduced numbers of repeated tests

    Reduced sample volume

  • 35

    Flammable and combustible liquids in containers 5 gallons and more should be stored in: * 0/1 A flammable safety cabinet vented to room air A nonexplosion proof refrigerator A fume hood An approved safety can

    An approved safety can

  • 36

    Which of the following is the best choice for decontaminating bench tops contaminated by the AIDS virus? * 1/1 Sodium hypochlorite bleach Formalin Quaternary ammonium compound 100% alcohol

    Sodium hypochlorite bleach

  • 37

    When processing specimens for mycobacterial testing, what specific engineering control must be used? * 1/1 Horizontal laminar flow hood Barrier protection only Biological safety cabinet Fume hood

    Biological safety cabinet

  • 38

    An index of precision is statistically known as the: * 0/1 Median Mean Standard deviation Coefficient of variation

    Coefficient of variation

  • 39

    Friction against a rough surface: * 1/1 Laceration Hematoma Contusion Abrasion

    Abrasion

  • 40

    All of the following are composition of Bouin’s fluid except: * 1/1 Ethanol Glacial acetic acid Saturated aqueous solution of picric acid Formaldehyde

    Ethanol

  • 41

    Miscible with paraffin: * 0/1 Distilled water Ethanol Formalin Xylene

    Xylene

  • 42

    The precision of an instrument is validated by: * 0/1 Running the same sample multiple times Performing serial dilutions Processing unknown specimens Monitoring normal and abnormal control

    Running the same sample multiple times

  • 43

    To prevent injury, a safe lab work practice is to: * 1/1 Secure long hair and jewelry Store well-wrapped food in the supply refrigerator Wear contact lenses for eye protection Wear comfortable, rubber-bottomed, open-weaved shoes

    Secure long hair and jewelry

  • 44

    Safe handling and disposal of laboratory generated infectious waste require: * 0/1 Disinfection of all waste Thorough mixing of infectious and noninfectious waste Separation of infectious and noninfectious waste Incineration of all waste

    Separation of infectious and noninfectious waste

  • 45

    Paper or electronic report of lab results must include: * 0/1 The name of the person who collected the specimen The test price A pathologist's signature The name and address of the testing laboratory

    The name and address of the testing laboratory

  • 46

    The laboratory manager receives a complaint from the ICU about turnaround times for coagulation tests. The first step in problem solving should be: * 1/1 Gather data on current times by shift Talk to staff about various solutions Perform root cause analysis Draw a process map to send to the ICU explaining why it takes so long

    Gather data on current times by shift

  • 47

    A technologist repeatedly misses tubercle bacilli when examining stained smears for acid-fast bacilli. What plan of action should the supervisor first take to correct this problem? * 1/1 Issue a written warning Send the employee to a workshop to improve his/her knowledge Review the diagnostic criteria with the employee and monitor progress Reassign employee to another part of the laboratory

    Review the diagnostic criteria with the employee and monitor progress

  • 48

    In quality control, ±2 standard deviations from the mean includes what percentage of the sample population? * 1/1 50% 75% 95% 98%

    95%

  • 49

    The following data are calculated on a series of 30 determinations of a serum uric acid control: mean = 5.8 mg/dl, 1 standard deviation = 0.15 mg/dl. If confidence limits are set at ±2 standard deviations, which of these ranges represents the allowable limits for the control? * 0/1 5.65 to 5.95 mg/dl 5.35 to 6.25 mg/dl 5.50 to 6.10 mg/dl 5.70 to 5.90 mg/dl

    5.50 to 6.10 mg/dl

  • 50

    Upon completion of a run of cholesterol tests, the technician recognizes that the controls are not within the 2 standard deviations confidence range. What is the appropriate course of action? * 0/1 Report the results without any other action Run a new set of controls Run a new set of controls and repeat specimens Recalibrate instrument and run controls

    Run a new set of controls and repeat specimens

  • 51

    Diagnostic specificity is defined as the percentage of individuals: * 0/1 With a given disease who have a positive result by a given test Without a given disease who have a negative result by a given test With a given disease who have a negative result by a given test Without a given disease who have a positive result by a given test

    Without a given disease who have a negative result by a given test

  • 52

    Which of the following statements about analytical (examination) errors is true? * 0/1 Analytical laboratory errors are easy for ordering providers to detect Analytical errors almost never happen in a CLIA accredited laboratory Analytical errors are not obvious to providers Analytical errors can be caused by poor patient preparation

    Analytical errors are not obvious to providers